Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Rezera postpones a planned $200M IPO shortly before expected debut

Rezera, a biotech developing drugs for cardio and inflammatory diseases, has delayed its IPO that was scheduled for Friday, a company spokesperson confirmed to Endpoints News. The spokesperson cited “current market conditions” as the reason ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Finance & Markets

More from Thursday 12 November →